Experienced in Homocystinuria due to MTHFR Deficiency

Tomohide Goto

Yokohama, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Homocystinuria due to MTHFR Deficiency
Yokohama, JP 
OverviewLocationsClinical Research

Overview

Tomohide Goto practices in Yokohama, Japan. Goto is rated as an Experienced expert by MediFind in the treatment of Homocystinuria due to MTHFR Deficiency. Their top areas of expertise are West Syndrome, Spasmus Nutans, GABA-Transaminase Deficiency, and Lennox-Gastaut Syndrome (LGS).

Their clinical research consists of co-authoring 53 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Homocystinuria due to MTHFR Deficiency.

Locations

Yokohama, Japan
Other Locations
Kanagawa, Japan
Tokyo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Other
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trial

53 Total Publications

Genome sequencing provides high diagnostic yield and new etiological insights for intellectual disability and developmental delay.
Genome sequencing provides high diagnostic yield and new etiological insights for intellectual disability and developmental delay.
Journal: NPJ genomic medicine
Published: March 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Goto's expertise for a condition
ConditionClose
      View All 41 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile